Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Ekso Bionics files to sell 874K shares of common stock for holders  17:25
07/02/20
07/02
17:25
07/02/20
17:25
EKSO

Ekso Bionics

$7.35 /

+0.04 (+0.55%)

 
ShowHide Related Items >><<
EKSO Ekso Bionics
$7.35 /

+0.04 (+0.55%)

EKSO Ekso Bionics
$7.35 /

+0.04 (+0.55%)

06/26/20 H.C. Wainwright
Ekso Bionics price target raised to $12 from $8 at H.C. Wainwright
01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
EKSO Ekso Bionics
$7.35 /

+0.04 (+0.55%)

EKSO Ekso Bionics
$7.35 /

+0.04 (+0.55%)

On The Fly
Fly Intel: Pre-market Movers » 09:03
06/26/20
06/26
09:03
06/26/20
09:03
GPS

Gap

$10.17 /

-0.24 (-2.31%)

, ZGNX

Zogenix

$28.12 /

-0.22 (-0.78%)

, AXSM

Axsome Therapeutics

$76.66 /

+1.22 (+1.62%)

, EKSO

Ekso Bionics

$7.29 /

+4.18 (+134.41%)

, VXRT

Vaxart

$6.26 /

+3.08 (+96.86%)

, BIG

Big Lots

$33.83 /

+0.59 (+1.77%)

, NKE

Nike

$101.46 /

+1.37 (+1.37%)

, APOG

Apogee Enterprises

$22.52 /

+1.19 (+5.58%)

, DBVT

DBV Technologies

$5.40 /

-0.04 (-0.74%)

, SOLY

Soliton

$11.82 /

-0.18 (-1.50%)

, IDEX

Ideanomics

$2.43 /

-0.68 (-21.86%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

VXRT Vaxart
$6.26 /

+3.08 (+96.86%)

SOLY Soliton
$11.82 /

-0.18 (-1.50%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

DBVT DBV Technologies
$5.40 /

-0.04 (-0.74%)

BIG Big Lots
$33.83 /

+0.59 (+1.77%)

AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

APOG Apogee Enterprises
$22.52 /

+1.19 (+5.58%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

06/22/20 Wells Fargo
Gap rallies after Wells double upgrade on 'compelling value unlocks'
06/08/20 Deutsche Bank
Gap price target lowered to $13 from $15 at Deutsche Bank
06/05/20 MKM Partners
Gap price target raised to $12 from $8 at MKM Partners
06/05/20 RBC Capital
Gap price target raised to $13 from $8 at RBC Capital
ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

06/26/20 Stifel
FDA approval of Fintepla provides 'sigh of relief' for Zogenix, says Stifel
05/05/20 Piper Sandler
Zogenix price target lowered to $56 from $64 at Piper Sandler
04/22/20 Piper Sandler
Zogenix Fintepla data supports broader utility, says Piper Sandler
04/01/20 Mizuho
Zogenix price target lowered to $64 from $71 at Mizuho
AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

06/26/20 H.C. Wainwright
Ekso Bionics price target raised to $12 from $8 at H.C. Wainwright
01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
VXRT Vaxart
$6.26 /

+3.08 (+96.86%)

04/30/20 H.C. Wainwright
Vaxart price target raised to $7 from $3 at H.C. Wainwright
08/15/19 Brookline
Vaxart initiated with a Buy at Brookline
06/27/19 H.C. Wainwright
Vaxart initiated with a Buy at H.C. Wainwright
BIG Big Lots
$33.83 /

+0.59 (+1.77%)

06/17/20 Piper Sandler
Piper boosts Big Lots estimates to Street-high, sees 'considerable upside'
05/26/20 Deutsche Bank
Big Lots price target raised to $31 from $19 at Deutsche Bank
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Goldman Sachs
Big Lots initiated with a Neutral at Goldman Sachs
NKE Nike
$101.46 /

+1.37 (+1.37%)

06/26/20 Morgan Stanley
Market understands Nike's near-term challenges, says Morgan Stanley
06/26/20 Credit Suisse
Nike price target lowered to $111 from $114 at Credit Suisse
06/26/20 UBS
Nike price target raised to $127 from $122 at UBS
06/26/20 Citi
Nike disappointments offset by quarter-to-date performance, says Citi
APOG Apogee Enterprises
$22.52 /

+1.19 (+5.58%)

04/03/20 DA Davidson
Apogee Enterprises price target lowered to $22 from $35 at DA Davidson
12/20/19 DA Davidson
Apogee Enterprises price target lowered to $35 from $40 at DA Davidson
06/28/19 Craig-Hallum
Apogee Enterprises price target raised to $52 after Q1 report at Craig-Hallum
DBVT DBV Technologies
$5.40 /

-0.04 (-0.74%)

06/26/20 Stifel
DBV restructuring 'not comforting for investors,' says Stifel
04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/20/20 Kepler Cheuvreux
DBV Technologies downgraded to Hold from Buy at Kepler Cheuvreux
SOLY Soliton
$11.82 /

-0.18 (-1.50%)

06/16/20 Roth Capital
Soliton price target raised to $16 from $14 at Roth Capital
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

SOLY Soliton
$11.82 /

-0.18 (-1.50%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

DBVT DBV Technologies
$5.40 /

-0.04 (-0.74%)

BIG Big Lots
$33.83 /

+0.59 (+1.77%)

AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

APOG Apogee Enterprises
$22.52 /

+1.19 (+5.58%)

  • 26
    Jun
  • 04
    Mar
  • 30
    Jan
  • 19
    Dec
  • 09
    Oct
ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

VXRT Vaxart
$6.26 /

+3.08 (+96.86%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

VXRT Vaxart
$6.26 /

+3.08 (+96.86%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

DBVT DBV Technologies
$5.40 /

-0.04 (-0.74%)

BIG Big Lots
$33.83 /

+0.59 (+1.77%)

AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

BIG Big Lots
$33.83 /

+0.59 (+1.77%)

AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

Recommendations
Ekso Bionics price target raised to $12 from $8 at H.C. Wainwright » 06:19
06/26/20
06/26
06:19
06/26/20
06:19
EKSO

Ekso Bionics

$7.29 /

+4.18 (+134.41%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Ekso Bionics to $12 from $8 and reiterates a Buy rating on the shares after the company received 501(k) clearance from the FDA to market its lead product, EksoNR robotic exoskeleton, for the treatment of patients with acquired brain injuries. The analyst believes that the addition of new indication bodes well for a stronger adoption and to treat a broader group of patients.

ShowHide Related Items >><<
EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

Hot Stocks
Ekso Bionics receives FDA clearance to market EksoNR robotic exoskeleton » 08:37
06/25/20
06/25
08:37
06/25/20
08:37
EKSO

Ekso Bionics

$3.11 /

-0.28 (-8.26%)

Ekso Bionics announced it…

Ekso Bionics announced it has received 501(k) clearance from the U.S. Food and Drug Administration to market its EksoNR robotic exoskeleton for use with patients with acquired brain injury. EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use with ABI, significantly expanding the device's indication to a broader group of patients. EksoNR is the next generation device of the most clinically used robotic exoskeleton, and was previously cleared by the FDA for stroke and spinal cord injury rehabilitation in 2016. The device was the first of its kind to receive a stroke indication and is now also the first to receive an ABI indication. EksoNR is cleared by the FDA for stroke, spinal cord injury, and acquired brain injury rehabilitation. The device is also CE-marked and available in Europe.

ShowHide Related Items >><<
EKSO Ekso Bionics
$3.11 /

-0.28 (-8.26%)

EKSO Ekso Bionics
$3.11 /

-0.28 (-8.26%)

01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
EKSO Ekso Bionics
$3.11 /

-0.28 (-8.26%)

Syndicate
Ekso Bionics files $75M mixed securities shelf  09:35
06/16/20
06/16
09:35
06/16/20
09:35
EKSO

Ekso Bionics

$3.77 /

+0.24 (+6.80%)

 
ShowHide Related Items >><<
EKSO Ekso Bionics
$3.77 /

+0.24 (+6.80%)

EKSO Ekso Bionics
$3.77 /

+0.24 (+6.80%)

01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
EKSO Ekso Bionics
$3.77 /

+0.24 (+6.80%)

Over a month ago
Syndicate
Ekso Bionics announces closing of $7.89M registered direct offering » 13:34
06/10/20
06/10
13:34
06/10/20
13:34
EKSO

Ekso Bionics

$3.81 /

-0.15 (-3.79%)

Ekso Bionics Holdings…

Ekso Bionics Holdings announced the closing of its previously announced registered direct offering of 1,747,704 shares of its common stock at a purchase price of $4.5145 per share and the concurrent private placement of warrants to purchase up to 873,852 shares of its common stock issued to the accredited investors in the registered direct offering priced at-the-market under Nasdaq Rules, for aggregate gross proceeds of approximately $7.89M. The warrants are immediately exercisable, have an exercise price of $5.18 per share and a term of five and one-half years from the issuance date. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.

ShowHide Related Items >><<
EKSO Ekso Bionics
$3.81 /

-0.15 (-3.79%)

EKSO Ekso Bionics
$3.81 /

-0.15 (-3.79%)

01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
EKSO Ekso Bionics
$3.81 /

-0.15 (-3.79%)

Syndicate
Ekso Bionics announces $7.89M registered direct offering priced at-the-market » 09:12
06/08/20
06/08
09:12
06/08/20
09:12
EKSO

Ekso Bionics

$5.06 /

+0.16 (+3.27%)

Ekso Bionics Holdings…

Ekso Bionics Holdings announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,747,704 of its shares of common stock, at a purchase price of $4.5145 per share, in a registered direct offering priced at-the-market under Nasdaq Rules. The company has also agreed to issue to the investors in a concurrent private placement warrants to purchase up to an aggregate of 873,852 shares of common stock. The closing of the offering is expected to occur on or about June 10, 2020, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants have an exercise price equal to $5.18 per share, are exercisable immediately and will expire five and one-half years from the issuance date. The gross proceeds from the offering are expected to be approximately $7.89M. The company intends to use the net proceeds from the offering for working capital purposes and other general corporate purposes.

ShowHide Related Items >><<
EKSO Ekso Bionics
$5.06 /

+0.16 (+3.27%)

EKSO Ekso Bionics
$5.06 /

+0.16 (+3.27%)

01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
EKSO Ekso Bionics
$5.06 /

+0.16 (+3.27%)

Hot Stocks
Ekso Bionics announces CFIUS determination regarding China JV » 16:13
05/20/20
05/20
16:13
05/20/20
16:13
EKSO

Ekso Bionics

$3.21 /

+0.065 (+2.07%)

Ekso Bionics Holdings…

Ekso Bionics Holdings reported that the Company, Zhejiang Youchuang Venture Capital Investment and another partner received notice from the Committee on Foreign Investment in the United States, CFIUS, in connection with its review of the company's and the JV Partners' investment in Exoskeleton Intelligent Robotics. The notice states that CFIUS's prior national security concerns regarding the JV could not be mitigated and, in connection with its determination, CFIUS presented the Company and the JV Partners with a National Security Agreement, which will, among other things, require the termination of the Company's role with the JV. The Company intends to work cooperatively with the JV Partners and CFIUS to finalize the terms of the NSA. The JV was established in early 2019 with the purpose of developing and serving the exoskeleton market in China and other Asian markets and to create a global exoskeleton manufacturing center in the Zhejiang Province of China. Following U.S. governmental inquiries regarding the JV, the Company and the JV formally submitted a joint voluntary notice to CFIUS in December 2019 to review the transaction. CFIUS subsequently inquired about Ekso Bionics' legacy work for the U.S. government as well as technology transfers and other aspects of the JV and, in February 2020, imposed interim measures to mitigate identified concerns pending completion of its investigation. These measures temporarily suspended the Company's contributions to the JV and other integration activities for the JV. "Despite our best efforts to mitigate their concerns, we are disappointed that CFIUS will not allow us to move forward with the joint venture," said Jack Peurach, Chief Executive Officer of Ekso Bionics. "Although we looked forward to working with our JV partners, we are confident in our abilities to partner with other global manufacturing sources to continue our product cost reduction initiatives. The termination of the JV should not have a material impact on our operations during the remainder of 2020."

ShowHide Related Items >><<
EKSO Ekso Bionics
$3.21 /

+0.065 (+2.07%)

EKSO Ekso Bionics
$3.21 /

+0.065 (+2.07%)

01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
EKSO Ekso Bionics
$3.21 /

+0.065 (+2.07%)

Over a quarter ago
Earnings
Ekso Bionics sees Q1 revenue $1.4M-$1.5M, two estimate-consensus $3.63M » 16:08
04/09/20
04/09
16:08
04/09/20
16:08
EKSO

Ekso Bionics

$2.83 /

+0.02 (+0.71%)

The COVID-19 pandemic…

The COVID-19 pandemic impacted Ekso Bionics' business in the first quarter as its customers shifted their priorities to prepare for and manage their business during the pandemic. This has caused many of its customers to delay orders, which are typically booked in the last few weeks of a quarter. It is important to note that a majority of the Company's customers have indicated that their originally planned orders are delayed and not canceled, pending the return to a more normal environment. Total revenue for the first quarter of 2020 is estimated to be in the range of $1.4 - $1.5M. Cash at March 31, 2020 is estimated at $8.5M, compared to $10.9M at December 31, 2019. "The COVID-19 pandemic has impacted our customers' businesses, and subsequently, our business as customers delay longer-term technology decisions. As a result, we have shifted our business operations to reduce expenses and align our strategy with current market conditions," said Jack Peurach, President and Chief Executive Officer of Ekso Bionics. "As a company committed to meeting the needs of our customers, we are evolving our business so we can continue to support our customers while they focus their energy on protecting their patients and staff from COVID-19. We also took the difficult decision to furlough a portion of our dedicated and valued employees in order to weather this extraordinary global health crisis, bring expenses more in-line with business operations over the short-term, and allow us to resume normal activities when our customers are ready."

ShowHide Related Items >><<
EKSO Ekso Bionics
$2.83 /

+0.02 (+0.71%)

01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
Hot Stocks
Ekso Bionics announces 1-for-15 reverse stock split » 16:02
03/24/20
03/24
16:02
03/24/20
16:02
EKSO

Ekso Bionics

$0.22 /

+0.0171 (+8.27%)

Ekso Bionics announced…

Ekso Bionics announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of March 24. The company's common stock will open for trading on The Nasdaq Capital Market on March 25, on a split-adjusted basis under the existing trading symbol "EKSO". The company's common stock will trade under a new CUSIP number 282644301 upon the effectiveness of the reverse stock split. Upon the effectiveness of the reverse stock split, the number of shares of the company's outstanding common stock will decrease from approximately 87.44M pre-split shares to approximately 5.83M post-split shares, with no change in par value per share.

ShowHide Related Items >><<
EKSO Ekso Bionics
$0.22 /

+0.0171 (+8.27%)

01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
03/26/19 Aegis
Ekso Bionics initiated with a Buy at Aegis

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.